OXB Share Price Performance
UK£6.13
3.13 (104.67%)
27.3% undervalued intrinsic discount
UK£8.43
Fair Value
Price UK£6.13
AnalystConsensusTarget UK£8.43
AnalystHighTarget UK£11.70
AnalystLowTarget UK£5.50
Fair ValueUK£8.43
Share Pricen/a
Oxford Biomedica plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 36 Fair Values set on narratives written by author
OXB Community Narratives
AN
Fair Value
·Fair Value UK£8.43 27.3% undervalued intrinsic discount
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
Fair Value
·Fair Value UK£11.7 47.6% undervalued intrinsic discount
Expanding Global Cell And Gene Therapies Will Drive Vector Opportunities
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value UK£5.5 11.5% overvalued intrinsic discount
Rising Capital Costs And Fierce Competition Will Constrain CDMO Growth
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
Key Takeaways Expansion into AAV and other vector types reduces dependency risks and supports earnings growth through diversified revenue streams. Strategic initiatives and expanded operations within the cell and gene therapy market drive revenue growth and enhance market share opportunities.Read more
AN
UK£8.43
27.3% undervalued intrinsic discount
Fair Value
Profit Margin
13.91%
Future PE
31.04x
Price in 2029
UK£10.48
Expanding Global Cell And Gene Therapies Will Drive Vector Opportunities
Key Takeaways Strong commercial traction, technical leadership, and high pipeline maturity position the company for faster revenue and cash growth than sector trends suggest. Expanding use cases and regulatory tailwinds in cell and gene therapy boost recurring revenue prospects, with the stock undervaluing the long-term market opportunity.Read more
AN
UK£11.7
47.6% undervalued intrinsic discount
Fair Value
Profit Margin
14.72%
Future PE
38.06x
Price in 2029
UK£14.54
Rising Capital Costs And Fierce Competition Will Constrain CDMO Growth
Key Takeaways Rising borrowing costs, regulatory hurdles, and market commoditization threaten Oxford Biomedica's funding ability, profitability, and long-term financial targets. Client concentration and intensifying competition from larger industry players expose the company to revenue volatility and margin pressure.Read more
AN
UK£5.5
11.5% overvalued intrinsic discount
Fair Value
Profit Margin
12.96%
Future PE
15.51x
Price in 2029
UK£6.84
Trending Discussion
Recently Updated Narratives
AN
OXB: Future Performance Will Reflect Fast Track Platform Execution Success
Fair Value: UK£8.43 27.3% undervalued intrinsic discount
24 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OXB: Post Transition Buy Ratings Will Support Higher Quality Business Perception
Fair Value: UK£11.7 47.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OXB: Upgraded Rating Will Likely Expose Transition Risks In Execution
Fair Value: UK£5.5 11.5% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Oxford Biomedica plc Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.25
- 39.10%
- -17.85%
- 45.4%
About OXB
- Founded
- 1996
- Employees
- 977
- CEO
- WebsiteView website
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary ‘plug and play’ dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
